


Mutational Signature


Percent of SNVs
attributed to signature




Treatment

carboplatin
paclitaxel
liposomal doxorubicin
gemcitabine
cyclophosphamide
topotecan
cisplatin
olaparib
docetaxel
bevacizumab
etoposide
nab-paclitaxel
farletuzumab/placebo

Cisplatin *G. gallus*
Cyclophosphamide *G. gallus*
Etoposide *G. gallus*
Cisplatin *C. Elegans*
(1) Age
(2) BRCA
(3) MMR
(4) AID
(5) POLE
(6) AID
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25) MMR
(26)
(27)
(28)
(29) Tobacco
(30)



Pre-treatment



Post-treatment unique

